FMT in advanced cirrhosis: RCT feasibility trial, UK
278 gut metagenome samples from adult cirrhosis patients in the United Kingdom, from a placebo-controlled randomised feasibility trial of jejunal faecal microbiota transplant (FMT). machine-written summary
278 samples · 278 runs · GB · Adult · 2024 · 13.27 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 556 sample values (collection date, country) |
| ✓ Abstract / description | 556 sample values (health condition, health condition detail) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Faecal microbiota transplantation design randomized_controlled_trial · population liver_disease · FMT delivered via jejunum vs placebo in advanced cirrhosis patients
“placebo-controlled randomised-controlled feasibility trial of FMT transplanted into the jejunum” — bioproject.description (study level; per-sample arms are in the intervention column below)
FMT donor → recipient — not resolved
FMT vs placebo in cirrhosis; donor engraftment assessed by metagenomics; donor/recipient samples not distinguishable in archive metadata.
Genera, mean relative abundance over 250 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 278 | 100% | ||||
| country | 278 | 100% | 278 | |||
| health_condition | 278 | 100% | 278 | |||
| subject_id | 0 | 0% | ||||
| collection_date | 278 | 100% | 278 | |||
| health_condition_detail | 278 | 100% | 278 |
- Faecal microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial 2023 own_data
Archive description
Patients with liver cirrhosis have reduced gut bacterial diversity over-represented by pathobionts. This, coupled with increased gut permeability and bacterial translocation, increases susceptibility to infection and death. Faecal microbiota transplant [FMT] previously restored gut diversity and improved hepatic encephalopathy (HE) in 10 patients with cirrhosis. We performed a placebo-controlled randomised-controlled feasibility trial of FMT transplanted into the jejunum in 32 patients with advanced cirrhosis. The primary endpoint assessed safety, feasibility and tolerability of FMT. Secondary endpoints provided preliminary evidence of efficacy and mechanism. FMT was safe and well-tolerated with no serious adverse events. Deep metagenomic sequencing confirmed FMT increased recipient species richness with significant donor engraftment. FMT reduced intestinal barrier damage and systemic inflammation. FMT reduced microbial-associated ammonia production and augmented ammonia excretion via anaerobic metabolism of L-aspartate to hippurate providing proof of concept that FMT augments ammonia metabolism, central in the pathogenesis of HE, a debilitating complication of cirrhosis
How this project entered the registry
Classified as human gut / stool / blood / tissue / internal fluids shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.description · “cirrhosis have reduced gut bacterial diversity over-represented”
- body site external_curation.infant_catalog · “body_site_call gut”
- body site study.description · “Patients with liver cirrhosis have reduced”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA113767010 | collection_date | 2019 | R1 | 0.90 | biosample.attribute:collection_date | 2019 |
| SAMEA113767010 | country | GB | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | United Kingdom |
| SAMEA113767010 | health_condition | liver_disease | R4 | 0.50 | study.description | 32 patients with advanced cirrhosis |
| SAMEA113767010 | health_condition_detail | All patients have advanced liver cirrhosis | R4 | 0.50 | study.description | 32 patients with advanced cirrhosis |
Sequencing
278 runs over 278 samples · mean 14.06 Gbp per run (median 13.27 Gbp, total 3,907.85 Gbp; 278 runs with a base count) · layout PAIRED 278 · platform ILLUMINA 278 · models Illumina NovaSeq 6000 (278) · 90% of runs with a Sandpiper profile · first public 2024-09-16
Authors (24)
Shawcross D first · Edwards L · Woodhouse C · Lee S · Mullish B · Learoyd A · Portlock T · Flach C · Douiri A · Zamalloa A · Meoli L · Kronsten V · Yang X · Lynham S · Merrick B · Ribière C · Lelouvier B · Holmes S · Takis P · Marchesi J · Tranah T · Patel V · Shoaie S · Goldenberg S last
Downloads
PRJEB61882.csv.gz (7.0 KB) · parquet (78.8 KB) — all 278 samples, every field with route and confidence · PRJEB61882_determinations.csv.gz (5.6 KB) — 1,112 evidence rows